Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis

Annals of Oncology

Volumn 21, Issue 1, 2009, Pages 67-70

  Ishigami, H ^a   Kitayama, J ^a   Kaisaki, S ^a   Hidemura, A ^a   Kato, M ^a   Otani, K ^a   Kamei, T ^a   Soma, D ^a   Miyato, H ^a   Yamashita, H ^a   Nagawa, H ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Gastric cancer; i.p. chemotherapy; Paclitaxel; Phase II study; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; PACLITAXEL;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; ASCITES; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOLOGY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PERITONEUM METASTASIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 77949318561     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp260     Document Type: Article

References (30)

1. Sugarbaker PH, Yonemura Y. Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: best palliation with a ray of hope for cure. Oncology 2000; 58: 96-107.
2. Fujimoto S, Takahashi M, Kobayashi K et al. Relation between clinical and histologic outcome of intraperitoneal hyperthermic perfusion for patients with gastric cancer and peritoneal metastasis. Oncology 1993; 50: 338-343.
3. Ajani JA. Standard chemotherapy for gastric carcinoma: is it a myth? J Clin Oncol 2000; 18: 4001-4003.
4. Ohtsu A, Yoshida S, Saijo N. Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol 2006; 24: 2188-2196.
5. Yamao T, Shimada Y, Shirao K et al. Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascites: a report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group, JCOG 9603 Trial. Jpn J Clin Oncol 2004; 34: 316-322.
6. Oh SY, Kwon H-C, Lee S et al. A phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites. Jpn J Clin Oncol 2007; 37: 930-935.
7. Koizumi W, Narahara H, Hara T et al. S-1 plus cisplatin versus S-1 alone for firstline treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008; 9: 215-221.
8. Boku N, Yamamoto S, Shirao K et al. Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912). J Clin Oncol (Meeting Abstracts) 2007; 25: (Abstr LBA4513).
9. Boku N. Chemotherapy for metastatic disease: review from JCOG trials. Int J Clin Oncol 2008; 13: 196-200.
10. Ajani JA, Fairweather J, Dumas P et al. Phase II study of Taxol in patients with advanced gastric carcinoma. Cancer J Sci Am 1998; 4: 269-274.
11. Ohtsu A, Boku N, Tamura F et al. An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol 1998; 21: 416-419.
12. Yamada Y, Shirao K, Ohtsu A et al. Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol 2001; 12: 1133-1137.
13. Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 2000; 58: 191-197.
14. Mori T, Fujiwara Y, Yano M et al. Prevention of peritoneal metastasis of human gastric cancer cells in nude mice by S-1, a novel oral derivative of 5-fluorouracil. Oncology 2003; 64: 176-182.
15. Kobayashi M, Sakamoto J, Namikawa T et al. Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients. World J Gastroenterol 2006; 12: 1412-1415.
16. Fujitani K, Narahara H, Takiuchi H et al. Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer. Oncology 2005; 69: 414-420.
17. Mochiki E, Ohno T, Kamiyama Y et al. Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer. Br J Cancer 2006; 95: 1642-1647.
18. Narahara H, Fujitani K, Takiuchi H et al. Phase II study of a combination of S-1 and paclitaxel in patients with unresectable or metastatic gastric cancer. Oncology 2008; 74: 37-41.
19. Markman M, Rowinsky E, Hakes T et al. Phase I trial of intraperitoneal taxol: a Gynecologic Oncology Group study. J Clin Oncol 1992; 10: 1485-1491.
20. Francis P, Rowinsky E, Schneider J et al. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study. J Clin Oncol 1995; 13: 2961-2967.
21. Markman M, Brady MF, Spirtos NM et al. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study. J Clin Oncol 1998; 16: 2620-2624.
22. Armstrong DK, Bundy B, Wenzel L et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354: 34-43.
23. Fushida S, Fujita H, Kinami S et al. Effectiveness of intraperitoneal chemotherapy using new-aged drugs for the peritoneal dissemination of gastric cancer. Gan To Kagaku Ryoho 2005; 32: 1691-1694.
24. Tamura S, Miki H, Nakata K et al. Intraperitoneal administration of paclitaxel and oral S-1 for a patient with peritoneal dissemination and hydronephrosis due to advanced gastric cancer. Gastric Cancer 2007; 10: 251-255.
25. Kodera Y, Ito Y, Ito S et al. Intraperitoneal paclitaxel: a possible impact of regional delivery for prevention of peritoneal carcinomatosis in patients with gastric carcinoma. Hepatogastroenterology 2007; 54: 960-963.
26. Ishigami H, Kitayama J, Otani K et al. Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer. Oncology 2009; 76: 311-314.
27. Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma (2nd English Edition). Gastric Cancer 1998; 1: 10-24.
28. Lawless J. Statistical Models and Methods for Lifetime Data. Hoboken, NJ: John Wiley and Sons 1982; 108.
29. Sautner T, Hofbauer F, Depisch D et al. Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J Clin Oncol 1994; 12: 970-974.
30. Chang YF, Li LL, Wu CW et al. Paclitaxel-induced apoptosis in human gastric carcinoma cell lines. Cancer 1996; 77: 14-18.